Dasatinib News and Research

RSS

Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

Breast cancer is the second leading cause of cancer deaths among women in the United States. Many of these deaths occur when there is an initial diagnosis of invasive or metastatic disease. A protein called NEDD9-which regulates cell migration, division and survival-has been linked to tumor invasion and metastasis in a variety of cancers.

16 Jan 2013

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.

29 Nov 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company's investigational BCR-ABL inhibitor.

20 Aug 2012

Scientists identify new genetic alterations underlying high-risk subtype of ALL

Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies.

14 Aug 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).

16 Jun 2012

caprotec's CCMS technology identifies novel co-targets of three anti-cancer drugs

caprotec bioanalytics GmbH announced today the discovery of previously unknown specific drug-protein interactions for several anti-cancer drugs and the identification of potential novel co-targets of the drug molecules through the use of company's CCMS technology.

9 Dec 2011

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

9 Nov 2011

PKM2 enzyme has important non-metabolic functions in cancer formation

The embryonic enzyme pyruvate kinase M2 (PKM2) has a well-established role in metabolism and is highly expressed in human cancers. Now, a team led by researchers at the University of Texas MD Anderson Cancer Center reports in advance online publication of the journal Nature that PKM2 has important non-metabolic functions in cancer formation.

7 Nov 2011

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter of 2011 and provided an update on its corporate developments.

3 Nov 2011

New library for development of targeted cancer drugs

In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.

31 Oct 2011

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

18 Aug 2011

Taxoxifen combined with dasatinib reverses chemo-resistance in breast cancer cells

Taking a leukemia chemotherapy drug may help breast cancer patients who don't respond to tamoxifen overcome resistance to the widely-used drug, new research from the Kimmel Cancer Center at Jefferson suggests.

2 Aug 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Canadians newly diagnosed with a life-threatening blood cancer, chronic myeloid leukemia (CML) in chronic phase, now have a new treatment option available to them. Health Canada has granted a notice of compliance with conditions for SPRYCEL (dasatinib) as first-line treatment in patients with chronic phase CML.

22 Jul 2011

Medco announces new offerings within Advanced Oncology Solutions

Medco Health Solutions, Inc. today announced new offerings within its Advanced Oncology Solutions, that include treatment pathways decision support with embedded pharmacogenomic testing and nutrition recommendations for cancer patients.

20 Jul 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

LLS announces four new Academic Concierge partnerships for cancer drug development

With more than 320 academic science research grants currently in its portfolio, The Leukemia & Lymphoma Society (LLS) has made it a priority to help move promising discoveries more quickly from the laboratory to clinical trial and to patients with cancer.

7 Jun 2011